The research of Matthew J. Maurer is primarily collaborative, contributing data management, study design and statistical analysis expertise to researchers in the Mayo Clinic Cancer Center. As a member of the Biostatistics Core for two Specialized Programs of Research Excellence (SPORE), Maurer provides statistical support across many different fields, including molecular epidemiology, clinical trials, basic science with translational, immunological and correlative studies, next generation sequencing, and general clinical and pathology research. Maurer's personal research involves evaluation of biomarkers and clinical endpoints as well as development of prognostic models and indexes.
- Lymphoma Molecular Epidemiology Resource. Maurer is the statistician for the lymphoma Molecular Epidemiology Resource (MER), a multi-institution epidemiology registry of newly diagnosed lymphoma patients. The MER has enrolled more than 6,000 lymphoma patients since 2002. As the primary statistician, Maurer oversees the study's data content and directs the analysis of studies utilizing the MER.
- Novel endpoints and prognostic models. Maurer is working to identify patterns of clinical outcome in patients with lymphoma and ovarian cancer, with the goal of defining optimal endpoints of disease-related outcome in these populations. He is also developing prognostic models based on these endpoints using nomograms and electronic applications to facilitate use by clinicians, researchers and patients.
Significance to patient care
Maurer's aim is to improve research efficiency by identifying optimal clinical endpoints for evaluation of disease outcome in clinical trials and biological studies of lymphoma. Implementation of risk models into user-friendly nomograms and electronic applications will aid clinicians and patients in risk assessment and prognosis evaluation.